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Dr Scott Stevens (Knoxville, Tenn). This presentation from
Smolock, Lumsden, Davies and Team Vascular at TheMethodist/
DeBakey Heart & Vascular Center in Houston addresses the
important topic of outcomes for SFA interventions in patients with
metabolic syndrome. They studied 1014 SFA interventions over a
10-year period and found that nearly half of these were in patients
with metabolic syndrome. Their study showed that in this subset,
patients with metabolic syndrome were more likely to be female,
have more advanced lesions, and present with critical limb
ischemia. The study also demonstrated higher morbidity and
decreased clinical efficacy, as manifest by recurrent symptoms,
decreased patency, and more amputations. Of note, periproce-
dural mortality was not increased in patients with metabolic
syndrome. This study is important because it addresses out-
comes in the arena of lower extremity interventions and in the
era of comparative effectiveness, it is going to be all about
outcomes. Despite the huge increase of SFA interventions and
the wide array of therapeutic options available, we still have no
evidence-based data to guide us. It is pivotal that, as vascular
surgeons, we step up and participate in registries, trials, and critical
outcomes analysis to continue our leadership position and bring
the best treatment for our patients.
I would like to congratulate Dr Smolock and the vascular team
at The Methodist/DeBakey Heart & Vascular Center in Houston
for an excellent and timely paper.
Chris, I have four questions:
1. Your data showed higher periprocedural morbidity and worse
long-term outcomes, but not worse periprocedural mortality in
the patients with metabolic syndrome – any ideas why?
2. Do you think metabolic syndrome in this study was a surrogate
for anatomic and morphologic predictors of poor outcomes or
does it represent a systemic effect?
3. Because of worse outcomes in patients with metabolic syndrome,
have you raised the threshold for intervention in this subset?
4. Considering your results, what changes have you made in your
practice to reduce vascular risk factors in patients with meta-
bolic syndrome? iDr Christopher J. Smolock. Thank you, Dr Stevens. For
ortality, it was the same between the groups in the periprocedural
eriod. However, mortality was significantly higher for the meta-
olic syndrome group over the 5-year period. I think the similar
nd low mortality in the 30-day period reflects the fact that these
ere local procedures not done under general anesthesia. There
re some negative reports regarding patients with metabolic syn-
rome undergoing coronary procedures as well as general surgery
rocedures. This is attributed to these patients receiving general
nesthesia with a higher likelihood of systemic complications. We
id still see a systemic effect in our complication rate in the
eriprocedural period and that was not due to local complications
ut rather cardiac, renal, pulmonary, and other systemic types of
omplications. I also hope that the low periprocedural mortality
as to do with our risk reduction strategies preoperatively. This
lso leads into your last question about what we did differently. We
ound that our use of statins, -blockers, and aspirin were not at
he levels we would like them to be. Therefore, we have focused on
nitiating and maintaining these medications when appropriate on
ll of our patients preoperatively, perioperatively, and upon dis-
harge. In addition, if they meet criteria, we offer referral to a
ariatric center. Regarding your second question about small
argets, I do not think that the difference with metabolic syndrome
s due to poor or small targets. That is based on some of the data we
howed related to runoff score. By number of tibial vessels, which
as been related to better outcomes, there was no difference
etween the groups. There was also no difference between groups
s measured by SVS runoff score. Diabetes of course is a risk by
tself for poor targets or small targets so there may be something
here, but not that you could measure anatomically by the afore-
entioned metrics. And finally, regarding the general approach of
he group to intervening for this disease process, we try to be
onservative for claudication, unless it is life altering. We are
ggressive with an endovascular approach as a first line for critical
schemia.
